Loading...
Header Logo
Keywords
Last Name
Institution

Glen D Raffel MD, PhD

TitleAssociate Professor
InstitutionUniversity of Massachusetts Medical School
DepartmentMedicine
AddressMagenta Therapeutics
50 Hampshire Street, 8th Floor
Cambridge MA 02139
Phone857-242-0170
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentMedicine
    DivisionHematology Oncology

    InstitutionUMMS - Graduate School of Biomedical Sciences
    DepartmentCancer Biology


    Collapse Biography 
    Collapse education and training
    Bowdoin College, Brunswick, ME, United StatesBABiochemistry
    Tufts University School of Medicine, Boston, MA, United StatesMD
    Tufts University School of Medicine, Boston, MA, United StatesPHDMolecular Microbiology
    Collapse awards and honors
    1986 - 1989James Bowdoin Scholar, Bowdoin College
    1989Donald and Harriet Macomber Prize, Bowdoin College
    1989Summa cum laude in Biochemistry, Bowdoin College
    1995Allan MacLeod Cormack Award, Tufts University School of Medicine
    1998Alpha Omega Alpha, Tufts University School of Medicine
    1998William Dameshek Award in Internal Medicine, Tufts University School of Medicine
    2002Diplomate, Internal Medicine, American Board of Internal Medicine
    2004Diplomate, Medical Oncology, American Board of Internal Medicine
    2005Diplomate, Hematology, American Board of Internal Medicine

    Collapse Overview 
    Collapse overview

    The long-term ability of the body’s hematopoietic system to respond to hazardous stressors such as infection, bleeding or cytotoxic chemotherapy ultimately lies with the function of the hematopoietic stem cell (HSC). The defining property of the HSC is self-renewal, allowing replenishment of the cellular blood components over a lifetime. Long-term self-renewing HSCs are maintained in the quiescent G0 phase of the cell cycle through a complex interaction with the bone marrow niche. During proliferative stress, HSCs must enter the cell cycle to generate differentiated progeny to supply the body’s demands. Afterwards, HSCs must be able to return to quiescence, otherwise they will be depleted, leading to bone marrow failure and death. Therefore, pathways controlling the balance between HSC quiescence and proliferation are critically important and tightly regulated. Conversely, these same pathways are often dysregulated in hematopoietic malignancies.Glen Raffell Profile

    The OTT1(aka RBM15) gene was originally isolated as the 5’ fusion partner in the t(1;22)(p13;q13) translocation associated with infant acute megakaryocytic leukemia (AMKL). OTT1 is an ubiquitously expressed member of the spen family of developmental regulators, which are defined by the presence of three RNA-recognition motifs (RRM) and a spen paralog and ortholog (SPOC) domain. Ott1 is believed to be involved with alternative RNA splicing and nuclear export. The SPOC domain confers transcriptional activation/repressor function via an associated Hdac/Ncor/Smrt/Setd1b complex towards currently unknown native targets. A third domain is able to bind the Notch effector, Rbpj, and has been found to activate or repress Notch downstream effectors in a cell context-dependent manner. Constitutive activation through the Notch-effector, RbpJ?, contributes in part, to the oncogenic activity of the t(1;22) fusion product, OTT1-MAL.

    Using a conditional knockout approach in mice and deletion within the hematopoietic compartment, we demonstrated Ott1 has a significant role as a global hematopoietic regulator. Ott1 is required for pre-B development and has inhibitory roles in megakaryocyte, granulocytes and granulocyte/monocyte progenitor development. Although HSC populations are expanded in number after deletion, competitive repopulation experiments showed the HSCs were defective, thus demonstrating that Ott1 is required for HSC function. Further investigations revealed Ott1 is dispensable during steady-state hematopoiesis, however, it is required to maintain quiescence/self-renewal during proliferative stress. We have uncovered roles for Ott1 in the regulation of several processes critical to HSC function including quiescence, control of ROS, stress response and mitochondrial biogenesis. In addition, Ott1-deficient HSCs share many characteristics of prematurely aged HSCs, raising the possibility of Ott1-dependent control of aging-related pathways. The developmental requirement for Ott1 in other tissues such as heart and spleen and its near ubiquitous expression suggest these Ott1-dependent processes may play a more expansive role than confined to hematopoiesis.

    The ability to pharmacologically manipulate HSCs to expand, preserve self-renewal or better tolerate stress is a sought-after goal that would have far-reaching clinical benefits. HSC transplantation is limited by the quantities of available donor cells, particularly from umbilical cord sources, thus enabling in vitro graft expansion while preserving self-renewal capability would be invaluable. HSC exhaustion during cytotoxic chemotherapy is a major dose-limiting toxicity associated with considerable morbidity and mortality especially in the elderly. Likewise, HSCs in inherited and acquired bone marrow failure syndromes are unable to respond adequately to stressors such as infection or anemia.

    We are pursuing the molecular basis underlying the critical functions of Ott1 in hematopoietic and other tissues and how those functions are co-opted in t(1;22) AMKL. Ott1 is involved in control of transcription and splicing and our focus is to ascertain the targets with the aid of mouse genetic models. Our goal is to identify Ott1-dependent pathways important to HSC function to allow development of therapeutic interventions to guard HSC function during stress and impair function in malignant cells.



    Collapse Post Docs


    Post-Doctoral positions are available




    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Saini N, Cerny J, Furtado V, Desmond A, Zhou Z, Raffel G, Puthawala I, Bednarik J, Shanahan L, Miron P, Woda B, Ramanathan M, Nath R. Elderly do benefit from induction chemotherapy: High dose mitoxantrone based ("5+1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. Am J Hematol. 2018 Nov 12. PMID: 30417942.
      View in: PubMed
    2. Suzuki S, Racine RR, Manalo NA, Cantor SB, Raffel GD. Impairment of fetal hematopoietic stem cell function in the absence of Fancd2. Exp Hematol. 2016 Dec 01. PMID: 27915139.
      View in: PubMed
    3. Racine RR, Manalo NA, Hall JMF, Dibas A, Raffel GD, Mummert ME. CD44 induced enhancement of phosphatase activity and calcium influx: Modifications of EGR-1 expression and cell proliferation. Biochem Biophys Rep. 2016 Jul; 6:172-178. PMID: 28955875.
      View in: PubMed
    4. Zhang L, Tran NT, Su H, Wang R, Lu Y, Tang H, Aoyagi S, Guo A, Khodadadi-Jamayran A, Zhou D, Qian K, Hricik T, Côté J, Han X, Zhou W, Laha S, Abdel-Wahab O, Levine RL, Raffel G, Liu Y, Chen D, Li H, Townes T, Wang H, Deng H, Zheng YG, Leslie C, Luo M, Zhao X. Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. Elife. 2015 Nov 17; 4. PMID: 26575292.
      View in: PubMed
    5. Nan Xiao, Suparna Laha, Shankar P. Das, Kayla Morlock, Jonathan L. Jesneck and Glen D. Raffel. Ott1(Rbm15) regulates Thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl. Blood. 2014.
    6. Xiao N, Laha S, Das SP, Morlock K, Jesneck JL, Raffel GD. Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl. Blood. 2015 Feb 5; 125(6):941-8. PMID: 25468569.
      View in: PubMed
    7. Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante SV, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, Robinson GW, Hennighausen L, Gilliland DG, Kindler T. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. Cancer Res. 2013 Jan 1; 73(1):373-84. PMID: 23149921.
      View in: PubMed
    8. Cerny J, Yu H, Ramanathan M, Raffel GD, Walsh WV, Fortier N, Shanahan L, O'Rourke E, Bednarik J, Barton B, Kroll-Desrosiers A, Hao S, Woda B, Hutchinson L, Evens AM, Rosmarin AG, Nath R. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br J Haematol. 2013 Jan; 160(2):262-6. PMID: 23116454.
      View in: PubMed
    9. Xiao N, Jani K, Morgan K, Okabe R, Cullen DE, Jesneck JL, Raffel GD. Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress. Blood. 2012 May 24; 119(21):4898-907. PMID: 22490678.
      View in: PubMed
    10. Glen D. Raffel and Jan Cerny. Molecular Biology of Acute Leukemias. Cancer: Principles and Practice of Oncology. Devita, Lawrence and Rosenberg eds. 2011; 1916-1927.
    11. Mercher T, Raffel GD, Moore SA, Cornejo MG, Baudry-Bluteau D, Cagnard N, Jesneck JL, Pikman Y, Cullen D, Williams IR, Akashi K, Shigematsu H, Bourquin JP, Giovannini M, Vainchenker W, Levine RL, Lee BH, Bernard OA, Gilliland DG. The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest. 2009 Apr; 119(4):852-64. PMID: 19287095.
      View in: PubMed
    12. Raffel GD, Chu GC, Jesneck JL, Cullen DE, Bronson RT, Bernard OA, Gilliland DG. Ott1 (Rbm15) is essential for placental vascular branching morphogenesis and embryonic development of the heart and spleen. Mol Cell Biol. 2009 Jan; 29(2):333-41. PMID: 18981216.
      View in: PubMed
    13. Raffel GD, Mercher T, Shigematsu H, Williams IR, Cullen DE, Akashi K, Bernard OA, Gilliland DG. Ott1(Rbm15) has pleiotropic roles in hematopoietic development. Proc Natl Acad Sci U S A. 2007 Apr 3; 104(14):6001-6. PMID: 17376872.
      View in: PubMed
    14. Raffel GD, Gravallese EM, Schwab P, Joseph JT, Cannistra SA. Diagnostic dilemmas in oncology: case 2. Dermatomyositis and ovarian cancer. J Clin Oncol. 2001 Dec 1; 19(23):4341-3. PMID: 11731518.
      View in: PubMed
    15. Moy B, Wang JC, Raffel GD, Marcoux JP. Hemolytic uremic syndrome associated with clopidogrel: a case report. Arch Intern Med. 2000 May 8; 160(9):1370-2. PMID: 10809043.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Raffel's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _